Serigne Lo

The University of Sydney — Australia

Medicine · Health Sciences

58h-index14.7kcitations597works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cutaneous Melanoma Detection and Management(230), Cancer Immunotherapy and Biomarkers(136), Melanoma and MAPK Pathways(127), CAR-T cell therapy research(92), Immunotherapy and Immune Responses(91)

Publications593 total

A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making
Journal of the American Academy of Dermatology·2025Open Access
Intra-tumoural manganese is associated with radioresistance and overall survival in glioblastoma
Journal of Clinical Neuroscience·2025
Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Figure S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Letter Re: Critical evaluation of sentinel lymph node biopsy in pT1b and pT2a melanoma patients: A nationwide population-based study
European Journal of Cancer·2025
Supplementary Figure S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
2025Open Access
Preoperative predictors of priority outcomes of pelvic exenteration for locally recurrent rectal cancer: Results of the mixed-methods EviSurg study
European Journal of Surgical Oncology·2025
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
UNC Libraries·2025Open Access
Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR trial initial feasibility results
Journal of Geriatric Oncology·2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
Annals of Oncology·2025· 1 citedOpen Access
In vivo cutaneous confocal microscopy for diagnosing the lentigo maligna spectrum: A multicentre prospective study and proposal of a lentigo maligna spectrum score
Journal of the American Academy of Dermatology·2025
Predictors for adverse outcomes and recurrence of pyometra: a 10-year retrospective study
Hong Kong Journal of Gynaecology Obstetrics and Midwifery·2025Open Access
Evaluating educational interventions on healthcare students’ knowledge, attitudes, and practices (KAP) towards One Health in Hong Kong
CABI One Health·2025Open Access
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1–5 extracranial melanoma oligometastases (AXIOM)
BMC Cancer·2025Open Access
Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients
Immuno-Oncology Technology·2025Open Access
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
European Journal of Cancer·2025
Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors
2025Open Access
page 1 of 30Next →

Frequent Co-authors

Georgina V. Long(26), Alexander M. Menzies(23), Richard A. Scolyer(20), Matteo S. Carlino(15), John F. Thompson(11), Alexander Guminski(10), Robyn P.M. Saw(9), Shahneen Sandhu(8), Andrew J. Spillane(8), James S. Wilmott(7), Christian U. Blank(7), Richard Kefford(7), Helen Rizos(6), Grant A. McArthur(6), Paolo A. Ascierto(5), Kerwin F. Shannon(5), Alan Cass(5), Andrew Haydon(5), Inês Pires da Silva(4), Maria Gonzalez(4)